Ohio Marijuana Sales Top $331 Million in 2026, All-Time Purchases Pass $3.7 Billion Across 40.8 Million Transactions
- Ohio’s marijuana market has generated $331.8 million in combined sales in 2026 to date, with $49.3 million from medical marijuana and $282.5 million from non-medical sales.
- All-time marijuana sales in Ohio have reached over $3.7 billion across more than 40.8 million transactions.
- The average price of dried cannabis flower currently stands at $6.45 per gram, slightly down from $6.61 a year ago.
- Ohio’s cannabis infrastructure is expanding, featuring 209 dual-use dispensaries, numerous cultivators, processors, testing labs, and provisional licenses indicating ongoing retail growth, along with nearly 470,000 registered medical marijuana patients.
Ohio’s marijuana market continues to grow at a steady pace, with state figures showing $331,833,272 in combined sales in 2026, as of April 11.
That includes $49,339,466 in medical marijuana sales and $282,493,806 in non-medical sales so far this year, according to a new report by the Division of Cannabis Control. All-time marijuana sales have now reached $3,717,055,884 across 40,866,607 different transactions.
The current average cost per gram of dried cannabis flower is $6.45 per gram, a slight decrease from the $6.61 average roughly a year ago.
The report also shows the market’s infrastructure continuing to expand. As of April 20, Ohio had 209 dual-use dispensary certificates of operation, along with 37 cultivator certificates, 46 processor certificates and six testing laboratories. The state also listed 11 RFA II provisional dispensary licenses and 61 10(B) provisional licenses, signaling that additional retail growth could still be on the horizon.
On the medical side, Ohio had 469,870 registered patients as of March 31, along with 42,585 registered caregivers and 506 physicians holding certificates to recommend marijuana. The state says 458,780 unique patients had purchased medical marijuana as reported to OARRS by licensed dispensaries as of March 15. Altogether, the numbers show a market that is no longer in its early stages, but one that continues to post major sales while supporting a large patient population and a growing adult-use industry.